Pfizer (NYSE:PFE) Shares Up 2.6% – Here’s What Happened

Pfizer Inc. (NYSE:PFE) was up 2.6% during mid-day trading on Monday . The company traded as high as $27.82 and last traded at $27.7510. Approximately 45,805,413 shares were traded during mid-day trading, a decline of 0% from the average daily volume of 45,827,262 shares. The stock had previously closed at $27.04.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Investor buying tied to renewed interest in Pfizer’s GLP‑1 program — coverage notes that PFE remains on Jim Cramer’s list of GLP‑1/weight‑loss picks and that shares have risen since his “pass” comment, reflecting momentum around Pfizer’s monthly GLP‑1 candidate and retail attention. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: High retail interest — Zacks reports Pfizer among the most‑searched stocks on its site recently, a sign of increased retail attention that can amplify price moves and liquidity around news events. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Positive Sentiment: Long‑term bullish commentary — The Motley Fool publishes a bullish take arguing Pfizer’s diversified portfolio and ability to pivot support a long‑term buy case despite being behind leaders in GLP‑1s. This helps sentiment among buy‑and‑hold investors. Prediction: Buying Pfizer Stock Today Could Set You Up for Life
• Positive Sentiment: Income appeal — Pfizer is listed among large‑cap stocks with high dividends, which supports demand from income investors and can reduce volatility. Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Analyst consensus remains lukewarm — MarketBeat/analyst tallies show a consensus “Hold” with more holds and sells than buys, indicating limited near‑term upgrades to propel a sustained rally. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Neutral Sentiment: Technical/volume context — Today’s price moved higher but on volume below the stock’s 3‑month average, so follow‑through will depend on whether higher attention (searches/coverage) sustains buying interest.
• Negative Sentiment: Competitive and technology risks — Sector‑level moves such as Eli Lilly’s large AI/drug‑discovery deal underscore accelerating competition and technological differentiation among peers, which could pressure Pfizer’s market share and long‑term drug pipeline competitiveness. Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. HSBC upped their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a report on Thursday, February 12th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. Finally, Royal Bank Of Canada began coverage on Pfizer in a research note on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.19.

Pfizer Trading Up 2.6%

The stock has a market cap of $157.80 billion, a P/E ratio of 20.41 and a beta of 0.47. The stock’s 50-day moving average is $26.84 and its two-hundred day moving average is $25.70. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the firm posted $0.63 EPS. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently made changes to their positions in the company. Stance Capital LLC increased its stake in Pfizer by 26,746.0% in the 4th quarter. Stance Capital LLC now owns 26,846 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 26,746 shares during the last quarter. Rockefeller Capital Management L.P. raised its holdings in shares of Pfizer by 27.1% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,842,275 shares of the biopharmaceutical company’s stock worth $45,873,000 after acquiring an additional 392,913 shares in the last quarter. World Investment Advisors boosted its position in shares of Pfizer by 11.2% during the 4th quarter. World Investment Advisors now owns 397,952 shares of the biopharmaceutical company’s stock valued at $9,909,000 after acquiring an additional 40,239 shares during the last quarter. Nalls Sherbakoff Group LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $92,000. Finally, DUTCH ASSET Corp purchased a new position in shares of Pfizer in the fourth quarter valued at $237,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.